- Previous Close
262.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
262.00 - 262.00 - 52 Week Range
164.00 - 770.40 - Volume
0 - Avg. Volume
8 - Market Cap (intraday)
12.002B - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-217.67 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
www.ginkgo.bioRecent News: DNA.MX
View MorePerformance Overview: DNA.MX
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNA.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNA.MX
View MoreValuation Measures
Market Cap
7.68B
Enterprise Value
5.74B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.90
Price/Book (mrq)
1.03
Enterprise Value/Revenue
1.23
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-240.94%
Return on Assets (ttm)
-19.67%
Return on Equity (ttm)
-60.34%
Revenue (ttm)
227.04M
Net Income Avi to Common (ttm)
-547.03M
Diluted EPS (ttm)
-217.67
Balance Sheet and Cash Flow
Total Cash (mrq)
561.57M
Total Debt/Equity (mrq)
65.32%
Levered Free Cash Flow (ttm)
-235.06M